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Peter Sasieni, professor of biostatistics and cancer epidemiology Alejandra Castanon, epidemiologist Jack
Cuzick, John Snow professor of epidemiology
ABSTRACT
Objective To study the effect of cervical screening on
incidence of cervical cancer as a function of age with
particular focus on women screened under the age of 25.
Design Population based case-control study with
prospectively recorded data on cervical screening.
Setting Selected centres in the United Kingdom.
Participants 4012 women aged 20-69 with invasive
cancer diagnosed in participating centres and two
controlspercaseindividuallymatchedonageandareaof
residence.
Main outcome measures Odds ratios for strength of
association between cervical cancer and screening at
particular ages.
Results There is no evidence that screening women aged
22-24reducedtheincidenceofcervicalcanceratages25-
29 (odds ratio 1.11, 95% confidence interval 0.83 to
1.50). Similar results were seen for cancers restricted to
squamous carcinoma or FIGO (International Federation of
Gynaecology and Obstetrics) stage IB or worse, but the
numbers are insufficient to provide narrow confidence
intervals.Screeningwasassociatedwitha60%reduction
of cancers in women aged 40, increasing to 80% at age
64. Screening was particularly effective in preventing
advanced stage cancers.
ConclusionsCervicalscreeninginwomenaged20-24has
littleornoimpactonratesofinvasivecervicalcancerupto
age 30. Some uncertainly still exists regarding its impact
on advanced stage tumours in women under age 30. By
contrast, screening older women leads to a substantial
reduction in incidence of and mortality from cervical
cancer.Thesedatashouldhelppolicymakersbalancethe
impact of screening on cancer rates against its harms,
such as overtreatment of lesions with little invasive
potential.
INTRODUCTION
Cervical screening is a complex process that requires
careful analysis to determine the balance between its
benefits and harms. For society it is important to
show that screening will provide a net benefit at an
affordable cost. These issues have been given promi-
nence in the recent public controversy regarding
screening in women aged 20-24.
Unfortunately policy makers are often forced to
make decisions based on limited evidence. Such was
the situation in 2003, when the screening programme
inEnglandwasreorganised.Oneofthosechanges—to
first invite women for cervical screening only once
they reached the age of 25 (instead of between 20 and
24)—was and has remained controversial.
1-6 The deci-
siontochangeandstandardisetheageatfirstinvitation
was based, in part, on an earlier paper of ours, which
showed that the relative reduction in frank invasive
cervical cancer associated with screening was substan-
tially less in women aged 20-34 than it was in older
women.
7
The existing literature is limited partly because cau-
sal inference from case-control studies is hampered by
severalbiasesandthepossibilitythatfactorsotherthan
those studied are driving the observed associations.
Nevertheless, in the absence of randomisedcontrolled
trials addressing the particular question of interest,
careful analysis of well designed observational studies
providesthebestevidenceonwhichtomodifyexisting
screening programmes. The landmark meta-analysis
fromtheInternationalAgencyforResearchonCancer
(IARC) provided no details regarding the age depen-
dence of the results, but stated that “age did not affect
eitherthesensitivityofcytologicalscreeningorthedis-
tribution of the sojourn time of the disease. In particu-
lar,therewasnoevidencethatyoungerwomen(under
35) were more at risk of developing fast growing
tumours.”
8Wepreviouslycarriedoutasimilaranalysis
on UK data in three age groups: 20-39, 40-54, and 55-
69. We found that the reduction in risk three to five
years after a normal smear result was greater in the
older age groups.
7 Our finding was confirmed by a
smallerItalianstudy
9and,toalesserextent,byarecent
paperfromAustralia,
10butanimportantSwedishaudit
found no evidence of screening being less effective in
young women.
11
Here we studied how the association between cervi-
cal screening and a subsequent decrease in cervical
cancer varies with age. We used a substantially
enlarged dataset from the UK by estimating the odds
ratiosassociatedwithscreeninginoverlappingnarrow
age bands. Additionally, we focused on the age at
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cancers are diagnosed.
METHODS
Participants
Womendiagnosedwithcervicalcancerwereidentified
from histology laboratory records between January
1990 and April 2008. Local collaborators collected
case-control data for a year at a time. Different centres
collected cases over differing time periods depending
on the availability of a collaborator. (See table on
bmj.comfora breakdownofcasesbyyearofdiagnosis
and region of residence within the UK.) Women with
invasive (including micro-invasive) cervical cancer
were classed as cases. Eligible controls were women
who had ever been registered with a National Health
Service(NHS)generalpractitioner(andhadnotsubse-
quentlydiedoremigrated).Suchwomenhavearecord
inthenationalcervicalscreeningcall/recallsystem.All
controlswereindividuallymatchedtocasesonageand
place of residence: one control had the same general
practitioner as the case and a second had a different
general practitioner but was within the same adminis-
trative area. Occasionally, only one control could be
identified. The use of the same general practitioner
provided a crude surrogate for socioeconomic status
and ethnicity. We selected a control from a different
general practitioner to avoid overmatching as screen-
ing uptake is closely related to the general practi-
tioner’s enthusiasm for cervical screening. We
excluded cases not in the call/recall system at the
time of diagnosis (because such women could not be
selected as controls). Control selection was done
blinded to the screening information and in most
cases by randomselection (with a computer program).
Data were collected on all selected controls so there
was no selection or participation bias. Data on screen-
ing histories were abstracted from routinely recorded
cervicalcytologyrecordsheldonthecall/recallsystem
(and as such were not subject to recall bias). These
records include all NHS (and many private) smear
tests carried out in the UK since 1988. After local
NHS staff linked screening data to cases and controls,
the data were anonymised before being transferred to
us for analysis. Details of the design have been pub-
lished previously.
712
After the publication of the paper in 2003 we found
that40oftheoriginalcaseshadbeenduplicated(thatis,
the same woman wasreported twice). As we have now
removedtheduplicatesfromthedatabasethenumbers
of cases reported in the original article and the num-
bers of “previous” cases reported here are not the
same. Figure 1 provides a breakdown of cases used
throughout this paper.
Statistical methods
We used conditional logistic regressionto estimate the
association between having an adequate smear test
taken in a particular three year age band (such as 22-
24) with the incidence of cervical cancer in the subse-
quentfiveyearband(suchas25-29).Theassociationis
expressedastheoddsratiofordevelopingcervicalcan-
cer in the next five year interval in those screened in a
given (three year) age band compared with those not
screened in that age band or in the two previous years.
We repeated these analyses in overlapping age bands
(that is, screening at 22-24, 23-25, 24-26, etc). All age
bandsareinclusive(thatis,22-24means≥22and<25).
See appendix I on bmj.com for further details, includ-
ing the results of sensitivity analyses.
To ensure that age differences in effectiveness were
not attributable to a different impact of screening on
micro-invasive cancer or on adenocarcinoma, we
looked at the effect of screening separately by stage
andhistology.Finally,weconsideredbothallavailable
data and only data obtained subsequent to our pre-
vious publication.
7 The latter was done to examine
possible trends associated with changes in screening
policy and practice.
Inanattempttounderstandthereasonforscreening
beinglesseffectiveinyoungwomenwealsolooked,by
agegroup,attheproportionofcasesclassifiedasscreen
detected, prevalent, interval, never screened or lapsed
and “after an abnormal smear result”. See appendix II
on bmj.com for the intuitive description (as well the
formal definition) of these categories.
Analyses were done in Stata 10 (StataCorp, College
Station, TX).
RESULTS
Association between screening and cervical cancer at
different ages
Figure2showsthemainresults,withselecteddetailsin
table 1.Weincluded4012womenwithcervicalcancer
(any stage, including IA) diagnosed between 1990 and
2008 (including 1709 diagnosed since 2000) and 7889
controls. Figure 2 shows the odds ratio of cervical can-
cerinscreenedversusunscreenedwomenasafunction
of age. At older ages the odds ratios are substantially
below 1.0. They increase with decreasing age and are
greater than 1.0 for those screened at age 20-22. The
oddsratiosrelatetocancersdiagnosedinaspecificage
bandfor women screenedduring a previous ageband.
Forexample,theestimatedoddsratioof0.26plottedat
a screening age band of 52-54 is to be interpreted as
follows:therelativeriskofhavingcervicalcancerdiag-
nosed at age 55-59 is about 0.26 in women screened at
age 52-54 compared with women not screened
between ages 50 and 54. These odds ratios vary from
0.18 to 0.36 in age bands from 40-42 to 62-64,
Previous cases (n=2752)
Duplicates excluded
from this paper (n=40)
New cases (n=2247)
Cases included in this paper (aged 20-69 at diagnosis)
Previous (n=2191), new (n=1821), total (n=4012)
Cases in women under
age 20 (n=3), over age
69 (n=943) or diagnosed
before 1990 (n=1)
Fig 1 | Cases included in this paper
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ciated with a reduction in the risk of cervical cancer
over the subsequent five to eight years of between
64% and 82%. In younger women the effect of screen-
ing is substantially and significantly less. Screening at
ages 30-37 is associated with a reduction in the risk of
cervicalcanceroverthenextfiveyearsofbetween43%
and 60% (see broken lines on fig 2). The odds ratio for
screening in the age band 22-24 is 1.11 (95% confi-
denceinterval0.83to1.50)(table 1). Similarestimates
were obtained for screening at 20-22 and 21-23 (fig 2).
Thus screening at ages 20-24 has no detectable impact
on cervical cancer rates at ages 25-29.
We also looked separately at the data on 1821 cases
collected since our previous publication (figure not
shown). The pattern was similar to that for all the
data. In particular, odds ratios were still close to 1.0
for women screened at age 20-25.
Association between screening at different ages and
cervical cancer by stage and histological type of cancer
Figure3showsthesensitivityoftheseresultstostageor
histological type of cancer, or both. The overall pat-
terns are similar to those in figure 2. In particular,
when restricted to stage IB+, the odds ratios are not
significantly different from unity at young ages; as
before they fall rapidly with increasing screening age
from 25 to 34 years and then become fairly flat with a
nadiraroundage55.Theoddsratiosareevenlowerfor
moreadvanceddisease,showingthatadvancedcancer
isparticularlyrareinscreenedwomen.Thepatternfor
women with stage II or worse cancer is slightly differ-
entwithadipatage22-24andasecondpeakatage25-
28.Therewereonly38casesofadvancedcancer(stage
II or worse) in women under age 30 so the estimated
confidence intervals (fig 3d) are wide.
Despite there being over 350 women with cervical
cancer (any stage) aged 25-29, there is no indication of
any benefit of screening at age 22-24 (compared with
those not screened at age 20-24) (1.11, 0.83 to 1.50)
(table 1). Restriction of analysis to stage IB+ cervical
cancer made little difference to the point estimate, but
resulted ina widerconfidence interval andallowed for
the possibility of a greater effect (1.03, 0.63 to 1.7)
(fig3B).FurtherrestrictiontostageIB+cervicalcancer
in women aged 25-27 at diagnosis (see appendix I on
bmj.com)limitedtheanalysisto65womenandyielded
an estimated odds ratio of 0.52 (0.23 to 1.2).
Benefit associated with being screened twice by age 26
It has been argued that screening begins to be fully
effective only once a woman has been screened twice
and that consequently women screened aged 20-24
and again at age 25 will have a greater benefit from
screening after age 25 than will those who are first
screened at age 25. To study this we compared
women screened both at ages 20-22 and 23-25 with
those first screened only aged 23-25. In an analysis of
cancers diagnosed between ages 26.5 and 29.0 years
restricted to women who were screened between ages
23 and 25 (inclusive) the odds ratio for stage IB+
cancer associated with also being screened between
ages 20 and 22 (inclusive) was 0.90 (0.38 to 2.2). For
all cancers (including stage IA) the odds ratio was 1.1
(0.62 to 2.0).
Screening classification of diagnoses in women before age 25
There were 73 cancers diagnosed in women at age 20-
24 (inclusive). Of these 73 women, five had had no
previous smear tests, 32 were classified as screen
detected (13 on their first screen and 19 on subsequent
tests), 15 as interval cancers (last result was normal),
and in 21 the diagnosis followed a history of abnormal
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Fig 2 | Odds ratio for developing invasive cervical cancer stage
IA or worse (in the next five year interval) in those screened in
a given (three year) age band compared with those not
screened in that age band (or in two previous years). Odds
ratios plotted for overlapping age bands. Broken lines
indicate risk of developing cervical cancer at ages 33-40 and
43-65. Odds ratios and confidence intervals are truncated at
1.2. Figure is based on 4012 cases (including 437 in women
under age 30) and 7889 controls
Table 1 |Protective effect of screening in past against developing cancer (all stages) in future
Age (years) at diagnosis of cancer Cases (%) Controls (%) Odds ratio* (95% CI)
25-29
Screened age 22-24 202 (58) 399 (57) 1.11 (0.83 to 1.50)
Screened age 20-21, but not 22-24 46 (13) 70 (10) 1.51 (0.95 to 2.38)
Not screened aged 20-24 103 (29) 226 (33) 1.00
Total 351 (100) 695 (100) —
35-39
Screened age 32-34 346 (53) 842 (66) 0.55 (0.44 to 0.69)
Screened age 30-31, but not 32-34 88 (14) 144 (11) 0.79 (0.57 to 1.1)
Not screened aged 30-34 214 (33) 288 (23) 1.00
Total 648 (100) 1274 (100) —
45-49
Screened age 42-44 214 (45) 583 (63) 0.37 (0.29 to 0.48)
Screened age 40-41, but not 42-44 55 (12) 133 (14) 0.40 (0.27 to 0.58)
Not screened aged 40-44 203 (43) 207 (22) 1.00
Total 472 (100) 923 (100) —
55-59
Screened age 52-54 111 (33) 389 (58) 0.26 (0.19 to 0.36)
Screened age 50-51, but not 52-54 32 (9) 103 (15) 0.27 (0.17 to 0.43)
Not screened aged 50-54 198 (58) 183 (27) 1.00
Total 341 (100) 675 (100) —
*Calculated by conditional logistic regression taking account of matching
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cancers, 76% of stage IA cancers, and 81% of cancers
stage IB or worse occurred despite screening. We con-
sider cancers classified as interval, screen detected
(previously screened), and “after an abnormal result”
to have occurred despite screening.
Most screen detected (previously screened) cancers
were micro-invasive (12 out of 19 with known stage),
whereas most of the interval cancers were stage IB or
worse (12 out of 15 with known stage) (Fisher’se x a c t
test P=0.017). Of the 18 stage IB+ cancers in women
with a previous normal screening history, 11 (61%)
occurredwithin3.5yearsofanegativesmeartestresult.
We applied the same classification of screening history
to all women with cervical cancer stage IB or worse.
Table 3 shows the results in 10 year age groups . The
proportion of women with stage IB+ cancer who had
not been screened in the previous six years (never/
lapsed) increases with age. Compared with cases in
women aged 40-69, women aged 20-29 with stage IB+
cancer were far less likely to be classified as “never
screened.”
DISCUSSION
Thisstudyconfirmsourpreviousfindingsthatcervical
screening in women aged 20-34 is less effective than in
older women. By studying the effect of screening in
smaller age groups, we have shown that the efficacy
of screening decreases with decreasing age, even
within the age range 20-34.
Onaverage,participationinthe UKcervical screen-
ing programme by a woman aged 35-64 reduces her
risk of cervical cancer over the next five years by 60-
80%and herrisk ofadvancedcervical cancerby about
90%.Thebenefitofscreeningforwomenaged25-34is
moremodest.Screeninginwomenaged20-24haslittle
or no impact on the incidence of cervical cancer under
the age of 30. This applied whether we looked at all
cancers or restricted analysis to frankly invasive (that
is, stage IB or worse) squamous carcinoma, or even to
stage II or worse (fig 3). Because stage IB+ cancer is
rare in young women, however, the confidence inter-
vals are wide and our data do not rule out the possibi-
lity of screening in women aged 20-24 being effective
in reducing stage IB+ cancer in women aged 25-27.
Ithasalsobeenarguedthatwomenshouldhavetheir
first two smear tests close in time to minimise the
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Fig 3 | Effect of stage and histology type on odds ratio of developing cervical cancer (in next five year interval) given screening
in indicated age bands. Graph shows diagnosed cancer with five years of follow-up and compares those screened in the
previous three years with those not screened in the previous five years. A: 2589 cases (303 in women under age 30) and 5122
controls; B: 2448 cases (172 in women under age 30) and 4821 controls; C: 1525 cases (107 in women under age 30) and
3025 controls; D: 897 cases (38 in women under age 30) and 1764 controls
Table 2 |Screening history for women aged 20-24 at time of
diagnosis. Figures are numbers (percentages) of women
Screening category
Stage
IA IB+ Unknown Total
Screen detected:
First screen 6 (18) 5 (16) 2 (25) 13 (18)
Previously screened 12 (36) 6 (19) 1 (13) 19 (26)
Interval 2 (6) 12 (37) 1 (13) 15 (21)
After abnormal cytology 11 (33) 8 (25) 2 (25) 21 (29)
Never screened or lapsed 2 (6) 1 (3) 2 (25) 5 (7)
Total 33 (100) 32 (100) 8 (100) 73 (100)
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13 Our results
provide no evidence that women screened aged 20-22
and then again at 23-25 are better protected than those
screened only at age 23-25.
Acarefulreviewofthescreeninghistoriesofwomen
aged 20-24 with a diagnosis of cervical cancer suggests
that few (if any) of the cancers occurred through a lack
of screening. Indeed only five of these 73 women had
not been screened previously.
Strengths and weaknesses
We used prospectively recorded screening data and
selected controls at random, thus eliminating both
recall bias and selection bias (data were obtained for
all selected controls). We believe this design to be the
most appropriate given that a randomised controlled
trial was not possible. Other papers have analysed
trends in incidence of cancer (or mortality, or both)
before and after the introduction of screening to esti-
mate the impact of screening in the population.
14-17
Such analyses rely on comparison of observed rates
with estimates of what would have happened in the
absence of screening; they are subject to trends in
other factors such as the quality of the cancer registry
data. For women aged 20-29, who have been offered
screening from the age of 20, it is not possible to reli-
ably estimate what their rates would have been in the
absence of screening.
It is always possibleto criticiseobservational studies
as women who attend screening might differ from
those who do not so that any observed effect might
notbecausal.Fortheobserveddifferenceinthebenefit
ofscreeningatdifferentagestobecausedbyconfound-
ing,however,therewouldhavetobedifferencesinthe
wayconfoundersaffecttheresultsatdifferentages.We
knowofnoevidencetosupportsuchaninteractionand
suggest that differential benefits with age are not
caused by confounding but reflect the true effects of
screening.Wethinktherearefewbiasesinthisanalysis
andarecomfortableinviewingtheassociationsascau-
sal and using the term “protection offered by screen-
ing” to describe the odds ratios.
This large study of the impact of cervical screening
on invasive cervical cancer contains more cases than
all other studies with detailed screening information
combined. Some of the data presented have been
published previously, but over 45% are new. The
results of analyses limited to the new data are qualita-
tivelysimilartothoseusingallthedata,suggestingthat
there have been no changes in the impact of screening
in young women on rates of cervical cancer despite
improvements in the quality of screening in the UK.
The new analysis considers the association between
screening in one age group (for example, 25-29) and
cervical cancer in the subsequent five years (at ages
30-34 for this example). With this approach, the expo-
sure is close to the usual definition of screening cover-
age used by many screening programmes: the
proportion of eligible women screened in the past five
(or three) years. Furthermore, this approach more clo-
sely reflects what one could estimate by prospectively
following a cohort ofwomen.With a coverage interval
of three years and a follow-up of five years, however, it
couldbeasmuchaseight yearsbetweenthe last screen
and a diagnosis of cancer. Thus the benefit of regular
three (or five) yearly screening could be considerably
greater than that implied by this model. Nevertheless,
the approach does attempt to measure the protection
achieved with screening (from the treatment initiated
by a positive smear result) rather than the low risk per-
iods associated with a negative smear result.
Comparison with other studies
Much of the earlier literature aiming to study the pro-
tectionafforded by cervical screeningdidnot consider
the possibility of different levels of protection depend-
ing on age. An important recent paper reported on the
results of an audit of cervical cancer in Sweden.
11 The
odds ratios in that paper are similar for all age groups
withanoddsratioof0.42(1/2.37)fortheeffectofthree
yearly screening on incidence of cancer at ages 21-29.
It is important to consider the methodological differ-
ences between the analyses when interpreting these
results. They consider a woman (aged 20-52) to have
beenscreenedifshehadasmeartestbetween3.5years
and 6 months before (the date of the case’s) diagnosis.
TheyincludestageIAcancers,mostofwhichwillhave
been screen detected, as well as screen detected stage
IB cancer. Consider a screen detected cancer in a
woman who has two smear tests 3.5 years apart. If the
smear test that led to diagnosis is within six months of
diagnosis she will be classed as unscreened. A control
Table 3 |Distribution of cancers stage IB or worse according to screening classification. Figures are numbers (percentages)
of women
Screening category
Age (years) at diagnosis
20-29 30-39 40-49 50-59 60-69 Total
Screen detected:
First screen 25 (15) 131 (20) 115 (18) 87 (16) 86 (19) 444 (18)
Previously screened 33 (19) 121 (18) 93 (15) 47 (9) 20 (4) 314 (13)
Interval 54 (31) 196 (29) 143 (23) 127 (24) 106 (23) 626 (26)
After abnormal cytology 41 (24) 115 (17) 126 (20) 74 (14) 45 (10) 401 (16)
Never screened or lapsed 19 (11) 102 (15) 148 (24) 193 (37) 203 (44) 665 (27)
Total 172 (100) 665 (100) 625 (100) 528 (100) 460 (100) 2450 (100)
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chance of 86% (3.0/3.5) of having had a smear test in
the particular interval width of three years. Thus the
inclusion of screen detected cases introduces a consid-
erablebiasinfavourofscreening.Astheproportionof
cancers that are stage IA or screen detected stage IB is
greaterin youngwomen,the bias isparticularly strong
in youngwomen.To illustratethe point,the sameana-
lysis applied to women aged 20-29 in our study yields
an odds ratio of 0.46 (0.38 to 0.56).
Acase-controlstudyinNewSouthWales,Australia,
found that screening every two years seemed to be
more protective in women over the age of 30 than in
those aged 20-29.
10 The more favourable results for
screening in women aged 20-29 in that study could be
because their controls were selected from women who
had been for screening (albeit possibly only after the
date of diagnosis of the case).
Interpretation of the results
As we designed the study to eliminate most of the
biases that affect case-control studies, our observed
associations are almost certainly either causal or the
result of confounding. The heterogeneity of associa-
tionindifferentagebandswithinthesamestudyargues
strongly that these effects are real. There might be bio-
logicalreasonsforcervicalscreeningworkingbetterin
olderwomen.Undoubtedlythespecificityofscreening
is less in younger women because human papilloma-
virus (HPV) infections are so much more common.
This does not, however, explain why the sensitivity of
screening should be less. We favour the explanation
that, by necessity, a cancer in a woman aged 25
(infected at, say, 15 years) will have progressed from
HPV infection through cervical intraepithelial neopla-
sia grade III to cancer faster than in a woman aged 55
(infected at perhaps 25). This means that the opportu-
nities for detecting the small proportion of cervical
intraepithelial neoplasia grade III in women in their
early 20s that will progress to cancer within at most a
few years are small. It is an extreme example of length
bias: most cases of cervical intraepithelial neoplasia
grade III detected will be slow growing and could
safely be left for several years; but the rare cases that
are progressing rapidly will probably be missed.
It has been argued that screening from age 20 could
prevent more cancers in women aged 25-34 than
screening from age 25. Our study has little power to
detect such an effect. Policy decisions should be based
on balancing the benefits and harms of screening and
theneedtotakeintoaccounttheunderlyingriskofcer-
vical cancer at different ages. Such an analysis is
beyond the scope of this paper. We have provided
more accurate estimates of the benefits of cervical
screeningindifferentagegroups,whichshouldaidpol-
icy makers in making their decisions. As screening
undoubtedly leads to the detection of many cases of
stage IA cancer in women aged 20-24, one might
think it must be doing good by preventing more
advanced cancers. If this were the case, we should
have found that screening at ages 20-24 leads to a
reduction in stage IB+ cancers. That we found no
such reduction suggests that most of the stage IA can-
cers detected by screening women aged under age 25
would still be stage IA at ages 25-26 and could be
picked up by screening at age 25 without adverse con-
sequences.
This study is based on cancers diagnosed in the UK
between 1990 and 2008 and smears taken within the
UKfrom1988to2008.Cervicalcancerratesinwomen
in their 20s have been relatively high compared with
thosein othercountriesand abnormalcytologyresults
have been more common in those aged 20-34 than in
older women throughout this period.
1819 We believe
that the standard of smear taking, cytology reading,
and fail safe procedures for cervical screening in this
study have mostly been high. Since the early-mid
1990s the UK screening programmes have put great
emphasis on quality assurance, and there is evidence
that by the late 1990s, UK cytology was as good as (or
better than) anywhere in the world.
20 Thus our finding
thatcervicalscreeninginwomenaged20-24hasatbest
a modest effect on the incidence of cervical cancer at
ages 25-29 is almost certainly generalisable to other
countries. We have no reason to believe that it would
be substantially more effective elsewhere.
Any decision on when to start screening women will
havetoweighupbenefitsandharmsandmightdepend
on the local status quo. In a setting where screening is
offered to women aged 20-24 policy makers might
decide to continue this policy as we have not shown
that the harms exceed the benefits. By contrast, where
screening is not offered to women aged 20-24, the lack
of evidence of any benefit from screening in this age
group dictates that the policy should not change.
Unanswered questions and future research
Our study does not consider the harms of screening at
different ages nor do we take into account the absolute
rate of cervical cancer in screened and unscreened
women of different ages. Such a synthesis of research
is necessary for rational policy making. Undoubtedly,
however,decisionmakingwillbecomplicatedbecause
oftheuncertaintyinmanyoftheestimatesofharmand
benefit. As we have seen, the confidence intervals for
the impact of screening at ages 20-24 on stage II+ cer-
vical cancer are extremely wide. We have not even
attempted to estimate the added impact of starting
screening five years earlier on cancer at ages 30-44.
The most common harms of screening are the anxi-
ety caused by abnormal test results and the trauma of
treating cervical intraepithelial neoplasia that would
never have progressed to cancer. These can be easily
estimated. Treatment might be associated with prema-
ture delivery during subsequent pregnancies. If the
association observed in several studies
2122 is causal
then screening might do serious harm, but the associa-
tion might simply be because of confounding. These
issues require careful study.
The question of screening women aged 20-24 will
decrease in importance as the cohort of women vacci-
natedagainst HPV types16and18reachtheir20s.Ifit
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unvaccinated women aged 20-24, there can be no
doubt that the risk of cancer in women aged under 25
whoarevaccinatedbeforeexposuretoHPVwillbelow
enough to make screening at such an age unjustifiable.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Cervical screening has had a substantial impact on the incidence and mortality of cervical
cancer in many developed countries
Most of the benefit from screening comes from the prevention of cervical cancer, but it can
also lead to downstaging
The relative protection against cervical cancer might be less at ages 20-34 than in older
women
WHAT THIS STUDY ADDS
Cervical screening in women aged 20-24 is substantially less effective in preventing cancer
(and in preventing advanced stage tumours) than is screening in older women
The new methods for the analysis of case-control studies of screening avoid some of the
biases associated with previously used statistical methods
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